Skip to main content
. 2018 Aug 7;20(4):483–495. doi: 10.22074/cellj.2019.5591

Table 3.

Characteristics of enrolled subjects at the time of enrollment into study


Parameter Case group

Age (Y) (Mean ± SD, minimum-maximum) 55.6 ± 11.9, 43-70
Sex (male: female) 3:6
Cause of ESRD
Diabetic nephropathy 2
Hypertensive nephropathy 3
Poly cystic kidney disease 1
Recurrent UTI 1
Glumeronephritis 0
Unknown 2
Duration of ESRD (month) (Mean ± SD, minimum-maximum) 125.4 ± 76, 36-278
Previous HD (yes: no) 3:6
Duration of previous HD (month) (Mean ± SD, minimum-maximum) 36.7 ± 66, 0-193
Previous Tx (yes: no) 3:6
Duration of PD (month) (Mean ± SD, minimum-maximum) 77.1 ± 41.4, 24-124
Comorbidity
Diabetes (yes: no) 4:5
Hypertension (yes: no) 7:2
Transport status
Low 0
Low average 0
High average 6
High 3
Anuria (yes: no) 6:3
Ultrafiltration (ml/day) (Mean ± SD, minimum-maximum) 1216.6 ± 573.4, 300-2000
Weight (kg) (Mean ± SD) 67.2 ± 12.1
BMI (kg/m2) (Mean ± SD) 26.9 ± 5.3
SBP (mmHg) (Mean ± SD, minimum-maximum) 128.8 ± 18.3, 110-170
DBP (mmHg) (Mean ± SD, minimum-maximum) 80.5 ± 13.3, 65-110
MSCs administration (cell/kg) 1, 191, 631 ± 132, 327, 941, 176-1, 363, 636

ESRD; End-stage renal disease, UTI; Urinary tract infection, HD; Hemodialysis, Tx; Kidney transplant, PD; Peritoneal dialysis, BMI; Body mass index, SBP; Systolic blood pressure, DBP; Diastolic blood pressure, and MSCs; Mesenchymal stem cells.